A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

NCT00734474 on ClinicalTrials.gov · last registry update 2015-04-20

An unusually large phase 2/phase 3: 1,202 participants, more than double the 60 typical for the stage. The sponsor logged completion for June 2011. Primary outcome, as filed: Glycosylated Hemoglobin (HbA1c) Change From Baseline. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2/P3
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 1,202
Started: 2008-08
Primary completion: 2011-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glycosylated Hemoglobin (HbA1c) Change From Baseline

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.